Tag: Herpes Zoster (Shingles)
AAO: One Year of Valacyclovir Beneficial for Herpes Zoster Ophthalmicus
Significant treatment benefits seen at 18 months; in addition, risk for experiencing subsequent end points lower with valacyclovir
Herpes Zoster Linked to Increased Long-Term Risk for Cognitive Decline
HZ linked to increased risk for 3-unit increment in subjective cognitive decline score in the long term in Nurses' Health Study cohort
Two Doses of Recombinant Zoster Vaccine Highly Effective
Vaccine effectiveness wanes after one dose but remains relatively unchanged over four years after two doses
Effectiveness of Live Zoster Vaccine Wanes Over Time
Vaccine effectiveness highest in first year after vaccination and decreases considerably over time
Routine Vaccines Can Cut Risk for Later Alzheimer Disease
Findings seen for tetanus and diphtheria, shingles, and pneumococcus vaccines
Herpes Zoster Linked to Increased Risk for Cardiovascular Disease Events
Long-term risks for stroke and coronary heart disease increased for individuals with history of herpes zoster versus those with no history of herpes zoster
Herpes Zoster Not Linked to Increased Dementia Risk
Small reduction in risk for dementia seen after the first year for people with zoster versus general population comparators
Incidence of Herpes Zoster Up for ≥50s With COVID-19 Diagnosis
Increased herpes zoster risk found for those with versus without COVID-19, with more pronounced risk following COVID-19 hospitalization
Recommendations Updated for Recombinant Zoster Vaccine
Two doses of RZV recommended for adults 19 years and older who are immunocompromised due to disease or therapy
Concurrent Zoster, Flu Vaccines Tied to Lower Subsequent Flu Vaccine Uptake
Patients may misattribute adverse effects commonly caused by the zoster vaccine to the influenza vaccine
